Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Dr Reddy's Resolves Legacy Issues At Duvvada After FDA Clears Plant

Executive Summary

Dr Reddy’s has been given the all-clear for its Indian formulations manufacturing facility in Duvvada, Visakhapatnam, after the FDA issued an EIR closing out an inspection at the plant that has suffered longstanding quality issues.

You may also be interested in...



Manufacturing Round-Up: Sterling Completes Expansion As Xellia Teams With Civica Rx

Sterling Pharma Solutions completes an expansion of its UK pilot plant facility, Aphena invests, Dr Reddy’s and Asymchem get nods from the FDA, Ampersand Capital Partners acquires Germany’s Vibalogics, and Xellia strikes a deal with Civica Rx.

Dr Reddy’s Acquires Portfolio Of 42 ANDAs To Spur Growth In US

Dr Reddy’s is expanding its portfolio by acquiring 42 ANDAs in the US as it seeks to develop its North American and emerging market operations.

Manufacturing Roundup – 1 April 2019

Alvogen’s Lotus subsidiary and Cambrex are expanding their manufacturing capabilities in Taiwan and Canada respectively. As several firms reveal the results of FDA inspections, the agency slaps United Exchange Corporation with a warning letter.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

GB140097

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel